New targets for the treatment of ulcerative colitis: Gut microbiota and its metabolites
Computational and Structural Biotechnology Journal · 01.01.2025 · 27 · 1850-1863
DOI: 10.1016/j.csbj.2025.05.006 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Computational and Structural Biotechnology Journal, online erschienen am 09.05.2025. Verfasst von Huanyu Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Second Clinical Medical College, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi 712046, China. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 198 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Xi'an Medical University, Xi'an Science Technology Bureau, Education Department of Shaanxi Provincial government.
Abstract (Originalsprache)
Ulcerative colitis (UC) is one of the most common and difficult-to-treat inflammatory diseases Currently, the standard of care includes immunological modulation and anti-inflammatory medication to alleviate symptoms; however, these treatments are associated with several side effects. As a result, developing novel, safe, and effective treatment strategies is crucial. The gut microbiota and its influence on the onset and progression of UC through their regulation of immunity, barrier integrity, and homeostasis, serves as a promising target for UC therapy. In this review, we explore the pathological changes that take place in UC along with the role of gut microbiota and its metabolites in disease progression and modulation. Additionally, we offer a thorough description of novel UC treatment approaches that focus on altering the gut microbiota and its metabolites. These protocols include FMT, probiotics, prebiotics, and micro/nanoparticles. The ultimate goal is to offer a theoretical basis for the advancement of innovative therapeutic strategies for UC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Second Clinical Medical College, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi 712046, China.
- College of Basic Medical Sciences, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi 712046, China.
- Department of Gastroenterology, the First Affiliated Hospital of Xi'an Medical University, Xi'an, Shaanxi 710077, China.
Förderung
- Xi'an Medical University
- Xi'an Science Technology Bureau
- Education Department of Shaanxi Provincial government
- Shaanxi Province Natural Science Foundation
- Shanxi Provincial Key Research and Development Project
- Xi'an Medical University Affiliated Hospital
Zitieren
APA
Li, H., Pan, M., Li, Y., Cui, M., & Zhang, M. (2025). New targets for the treatment of ulcerative colitis: Gut microbiota and its metabolites. Computational and Structural Biotechnology Journal, 27, 1850-1863. https://doi.org/10.1016/j.csbj.2025.05.006
Vancouver
Li H, Pan M, Li Y, Cui M, Zhang M. New targets for the treatment of ulcerative colitis: Gut microbiota and its metabolites. Computational and Structural Biotechnology Journal. 2025;27:1850-1863. doi:10.1016/j.csbj.2025.05.006
BibTeX
@article{Li2025,
author = {Li, Huanyu and Pan, Meng and Li, Yifan and Cui, Manli and Zhang, Mingxin},
title = {New targets for the treatment of ulcerative colitis: Gut microbiota and its metabolites},
journal = {Computational and Structural Biotechnology Journal},
year = {2025},
volume = {27},
pages = {1850--1863},
doi = {10.1016/j.csbj.2025.05.006}
}
EUVIMED